| First Author | Ding Q | Year | 2017 |
| Journal | Clin Immunol | Volume | 183 |
| Pages | 145-157 | PubMed ID | 28844702 |
| Mgi Jnum | J:318446 | Mgi Id | MGI:6859700 |
| Doi | 10.1016/j.clim.2017.08.012 | Citation | Ding Q, et al. (2017) Ficolin-2 triggers antitumor effect by activating macrophages and CD8(+) T cells. Clin Immunol 183:145-157 |
| abstractText | Ficolin-2 is an important serum complement lectin. Here, we describe novel findings indicating that serum ficolin-2 concentrations in multiple tumor patients are significantly lower than those in healthy donors. Administration of exogenous ficolin-2 or ficolin-A (a ficolin-2-like molecule in mouse), with only once, could remarkably inhibit the tumor cells growth in murine tumor models via early macrophages, dendritic cells (DCs) and CD8(+) T cells, but not CD4(+) T cells. Ficolin-A (FCN-A) knockout (KO) mice exhibits significantly increased tumor cell growth. Ficolin-2 induces macrophage activation, promotes M1 polarization and facilitates proliferation and antigen-specific cytotoxicity of CD8(+) T cells. Ficolin-2 binds to Toll-like receptor 4 (TLR4) on macrophages and DCs and promotes their antigen-presenting abilities to CD8(+) T cells. Our findings provide a new therapeutic strategy for tumors based on the triggering of immune-mediated antitumor effect by ficolin-2. |
